Show simple item record

dc.contributor.authorUhlig, Till
dc.contributor.authorKaroliussen, Lars Fridtjof
dc.contributor.authorSexton, Joseph
dc.contributor.authorProvan, Sella Aarrestad
dc.contributor.authorKvien, Tore Kristian Aaserud
dc.contributor.authorHaavardsholm, Espen A.
dc.contributor.authorHammer, Hilde Berner
dc.date.accessioned2024-02-09T09:37:31Z
dc.date.available2024-02-09T09:37:31Z
dc.date.created2023-11-28T11:49:48Z
dc.date.issued2023
dc.identifier.citationRheumatology. 2023, 62 (12), 3886-3892.en_US
dc.identifier.issn1462-0324
dc.identifier.urihttps://hdl.handle.net/11250/3116549
dc.description.abstractObjectives In patients with gout there is a lack of longitudinal studies on the course of work productivity. We explored longitudinal changes in and predictors of work productivity over 2 years. Methods Patients in the NOR-Gout observational study with a recent gout flare and serum urate (sUA) >360 µmol/l attended tight-control visits during escalating urate lowering therapy according to a treat-to-target strategy. From the Work Productivity and Activity Impairment (WPAI) questionnaire, scores for work productivity and activity impairment were assessed over 2 years together with the Beliefs about Medicines Questionnaire and a variety of demographic and clinical variables. Results At baseline patients had a mean age of 56.4 years and 95% were males. WPAI scores at baseline were 5.0% work missed (absenteeism), 19.1% work impairment (presenteeism), 21.4% overall work impairment and 32.1% activity impairment. Work productivity and activity impairment improved during the first months, and remained stable at 1 and 2 years. Comorbidities were not cross-sectionally associated with WPAI scores at baseline, but predicted worse work impairment and activity impairment at year 1. The Beliefs about Medicines Questionnaire subscale with concerns about medicines at baseline independently predicted worse overall work impairment and worse activity impairment at year 1. Conclusions In patients with gout who were intensively treated to the sUA target, work productivity and activity impairment were largely unchanged and at 1 year predicted by comorbidities and patient concerns about medication.
dc.language.isoengen_US
dc.rightsNavngivelse 4.0 Internasjonal*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/deed.no*
dc.titleCourse and predictors of work productivity in gout - results from the NOR-Gout longitudinal 2-year treat-to-target studyen_US
dc.title.alternativeCourse and predictors of work productivity in gout - results from the NOR-Gout longitudinal 2-year treat-to-target studyen_US
dc.typePeer revieweden_US
dc.typeJournal articleen_US
dc.description.versionpublishedVersion
dc.source.pagenumber3886-3892en_US
dc.source.volume62en_US
dc.source.journalRheumatologyen_US
dc.source.issue12en_US
dc.identifier.doi10.1093/rheumatology/kead124
dc.identifier.cristin2203666
dc.relation.projectNorges forskningsråd: 328657
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode2


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Navngivelse 4.0 Internasjonal
Except where otherwise noted, this item's license is described as Navngivelse 4.0 Internasjonal